Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis - PubMed (nih.gov) Lehto J, Nylund M, Matilainen M, Sucksdorff M, Vuorimaa A, Rajander J, Wahlroos S, Hariri P, Airas L. Eur J Neurol. 2023 May 8. Epub ahead of print. 

 Positron emission tomography with [18 F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression - PubMed (nih.gov) Hamzaoui, M., Garcia, J., Boffa, G., Lazzarotto, A., Absinta, M., Ricigliano, V.A.G., Soulier, T., Tonietto, M., Gervais, P., Bissery, A., Louapre, C., Bottlaender, M., Bodini, B. and Stankoff, B. (2023), Ann Neurol.

In vivo characterization of microglia and myelin relation in multiple sclerosis by combined 11C-PBR28 PET and synthetic MRI - PubMed (nih.gov) Barletta VT, Herranz E, Treaba CA, Mehndiratta A, Ouellette R, Granberg T, Klawiter EC, Ionete C, Sloane JA, Mainero C. J Neurol. 2023 Jun;270(6):3091-3102. 

Association of serum neurofilament light with microglial activation in multiple sclerosis - PubMed (nih.gov) Saraste M, Matilainen M, Vuorimaa A, Laaksonen S, Sucksdorff M, Leppert D, Kuhle J, Airas L. J Neurol Neurosurg Psychiatry. 2023 May 2:jnnp-2023-331051. Epub ahead of print.

Katso Aubagion päivitetty valmisteyhteenveto täältä: Aubagio, INN - teriflunomide (europa.eu)